| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000002533 |
| Receipt No. | R000003085 |
| Official scientific title of the study | autologous hematopoietic stem cell transplantation followed by reduced intensity allogeneic stem cell transplantation for relatively young patients with multiple myeloma |
| Date of disclosure of the study information | 2009/11/01 |
| Last modified on | 2017/10/16 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | autologous hematopoietic stem cell transplantation followed by reduced intensity allogeneic stem cell transplantation for relatively young patients with multiple myeloma | |
| Title of the study (Brief title) | auto-allo HSCT for multiple myeloma | |
| Region |
|
|
| Condition | ||
| Condition | multiple myeloma | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluation of efficacy and safty of auto-HSCT followed by reduced intensity allotransplantation (cord blood or related donor) |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | survival rate of patients at 100 days from allotransplantation |
| Key secondary outcomes | overall survival, disease free survival and cummulative incidence of acute and chronic GVHD |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 2 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | auto-HSCT followed by reduced-intensity allotransplantation from related donor | ||
| Interventions/Control_2 | auto-HSCT followed by reduced intensity allotransplantation using cord blood | ||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Meet all three criteria of IMWG
2.PS 0 to 2(including patients with PS 3 to 4 because of only bone pain) 3.1.VC greater than 0.8,FEV1 greater than 0.7,normal diffusing capacity,PaO2 greater than 80mmHg,PaCO2 less than 45mmHg,SaO2 greater than 0.96 3.2.no abnormal findings in echocardiography, EF greater than 0.55 3.3.Within two fold of normal value in T.Bil G-GTP ALP GOT GPT 3.4.CCr greater than 50ml per min 3.5.Without active infection |
|||
| Key exclusion criteria | 1.Patients who recall approval
2.When stem cell source becomes not available 3.Patients with another severe disease 4.Patients who had received chemotherapy for maligancies other than multipul myeloma 5.Patients who is recognized as inadaptable for this trial |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Mineo Kurokawa |
| Organization | The university of Tokyo Hospital |
| Division name | Hematology and Oncology |
| Address | 7-3-1,Hongo,Bunkyo-ku,Tokyo |
| TEL | |
| Public contact | |
| Name of contact person | Yoichi Imai |
| Organization | The university of Tokyo Hospital |
| Division name | Hematology and Oncology |
| Address | |
| TEL | |
| Homepage URL | |
| imaiyo-tky@umin.ac.jp | |
| Sponsor | |
| Institute | The university of Tokyo Hospital,department of hematology and oncology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | The university of Tokyo Hospital,department of hematology and oncology |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003085 |